Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation

Critical Care Medicine

Volumn 37, Issue 7, 2009, Pages 2174-2179

  Siu, Chung Wah ^a   Lau, Chu Pak ^a   Lee, Wai Luen ^a   Lam, Kwok Fai ^a   Tse, Hung Fat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Amiodarone; Atrial fibrillation; Digoxin; Diltiazem; Ventricular rate control

Indexed keywords

AMIODARONE; DIGOXIN; DILTIAZEM; ANTIARRHYTHMIC AGENT;

AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HUMAN; HYPOTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SINUS RHYTHM; TREATMENT OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; HEART VENTRICLE TACHYCARDIA; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; DIGOXIN; DILTIAZEM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 67649800834     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a02f56     Document Type: Article

References (39)

1. Fuster V, Ryden LE, Cannom DS, et al: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354
2. McDonald AJ, Pelletier AJ, Ellinor PT, et al: Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. Ann Emerg Med 2008; 51:58-65
3. Wyse DG, Waldo AL, DiMarco JP, et al: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833
4. Van Gelder IC, Hagens VE, Bosker HA, et al: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840
5. Snow V, Weiss KB, LeFevre M, et al: Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009-1017
6. Chronic Conditions NCCF: Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London, Royal College of Physicians, 2006, p 9
7. del Arco C, Martin A, Laguna P, et al: Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med 2005; 46:424-430
8. Williams E, Ansari M, Lip GY: Managing atrial fibrillation in the accident and emergency department. QJM 2001; 94:609-614
9. Lip GY, Tse HF: Management of atrial fibrillation. Lancet 2007; 370:604-618
10. Falk RH: Atrial fibrillation. N Engl J Med 2001; 344:1067-1078
11. Kaufman ES, Zimmermann PA, Wang T, et al: Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: A multivariate analysis. J Am Coll Cardiol 2004; 44:1276-1282
12. Zimetbaum P, Ho KK, Olshansky B, et al: Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol 2003; 91:81-83
13. Delle Karth G, Geppert A, Neunteufl T, et al: Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29: 1149-1153
14. Ellenbogen KA, Dias VC, Plumb VJ, et al: A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multicenter study. J Am Coll Cardiol 1991; 18:891-897
15. Roberts SA, Diaz C, Nolan PE, et al: Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72:567-573
16. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group: Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997; 18:649-654
17. Jung SH, Hui S: Sample size calculation for rank tests comparing K survival distributions. Lifetime Data Anal 2002; 8:361-373
18. Dorian P, Jung W, Newman D, et al: The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36: 1303-1309
19. Jenkins LS, Brodsky M, Schron E, et al: Quality of life in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149:112-120
20. Rehnqvist N: Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study. Ann Clin Res 1981; 13(Suppl 30):68-72
21. Byrd RC, Sung RJ, Marks J, et al: Safety and efficacy of esmolol (ASL-8052: An ultrashortacting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll Cardiol 1984; 3:394-399
22. Amsterdam EA, Kulcyski J, Ridgeway MG: Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol 1991; 31:714-718
23. Salerno DM, Dias VC, Kleiger RE, et al: Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63: 1046-1051
24. Jordaens L, Trouerbach J, Calle P, et al: Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 1997; 18:643-648
25. Strasberg B, Arditti A, Sclarovsky S, et al: Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int J Cardiol 1985; 7:47-58
26. Hassan S, Ahmad S, Kamalakannan D, et al: Conversion of atrial fibrillation to sinus rhythm during treatment with intravenous esmolol or diltiazem: A prospective, randomized comparison. J Cardiovasc Pharmacol Ther 2007; 12:227-231
27. Demircan C, Cikriklar HI, Engindeniz Z, et al: Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J 2005; 22:411-414
28. Al-Khatib SM, LaPointe NM, Curtis LH, et al: Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol 2003; 91:91-94
29. Singh BN, Singh SN, Reda DJ, et al: Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861-1872
30. Chevalier P, Durand-Dubief A, Burri H, et al: Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis. J Am Coll Cardiol 2003; 41:255-262
31. Galve E, Rius T, Ballester R, et al: Intravenous amiodarone in treatment of recentonset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996; 27:1079-1082
32. Naccarelli GV, Wolbrette DL, Khan M, et al: Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 2003; 91: 15D-26D
33. Gheorghiade M, van Veldhuisen DJ, Colucci WS: Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113:2556-2564
34. Danias PG, Caulfield TA, Weigner MJ, et al: Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31:588-592
35. Vardas PE, Kochiadakis GE, Igoumenidis NE, et al: Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: A randomized, controlled study. Chest 2000; 117:1538-1545
36. Cotter G, Blatt A, Kaluski E, et al: Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J 1999; 20:1833-1842
37. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66:755-757
38. Marcus FI: The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1990; 66:366-367
39. Biffi M, Boriani G, Bronzetti G, et al: Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. Heart 1999; 82:176-182